The United States Patent and Trademark Office (USPTO) has granted Amgen Inc. patent US12583854B2, titled "KRAS G12C inhibitors and methods of using the same." This patent, effective March 24, 2026, covers specific KRAS G12C inhibitors and their application in treating various cancers, including pancreatic, colorectal, and lung cancers. The patent was filed on September 22, 2021, under application number 17482230 and includes 35 claims.

This patent grant signifies a new intellectual property right for Amgen, potentially impacting the competitive landscape for KRAS G12C inhibitor development and commercialization. While this is a patent grant and not a regulatory rule imposing direct compliance obligations on other entities, it is crucial for pharmaceutical companies and drug manufacturers operating in the oncology space to be aware of this granted patent. Companies involved in the research, development, or commercialization of similar KRAS G12C inhibitors should review the patent's claims to ensure their activities do not infringe upon Amgen's intellectual property rights.